ADMA Biologics Inc (ADMA)
18.10
-0.19
(-1.04%)
USD |
NASDAQ |
Jan 08, 13:00
ADMA Biologics SG&A Expense (Quarterly): 18.56M for Sept. 30, 2024
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Corcept Therapeutics Inc | 73.74M |
| Catalyst Pharmaceuticals Inc | 45.88M |
| Alnylam Pharmaceuticals Inc | 220.99M |
| Sarepta Therapeutics Inc | 128.20M |
| Stoke Therapeutics Inc | 12.69M |